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In asthma and chronic obstructive pulmonary disease, activation of
Gq-protein–coupled receptors causes bronchoconstriction. In each
case, the management of moderate-to-severe disease uses inhaled
corticosteroid (glucocorticoid)/long-acting β2-adrenoceptor agonist
(LABA) combination therapies, which are more efficacious than ei-
ther monotherapy alone. In primary human airway smooth muscle
cells, glucocorticoid/LABA combinations synergistically induce the
expression of regulator of G-protein signaling 2 (RGS2), a GTPase-
activating protein that attenuates Gq signaling. Functionally, RGS2
reduced intracellular free calcium flux elicited by histamine, meth-
acholine, leukotrienes, and other spasmogens. Furthermore, protec-
tion against spasmogen-increased intracellular free calcium, follow-
ing treatment for 6 hwith LABA plus corticosteroid, was dependent
on RGS2. Finally, Rgs2-deficient mice revealed enhanced broncho-
constriction to spasmogens and an absence of LABA-induced bron-
choprotection. These data identify RGS2 gene expression as a
genomic mechanism of bronchoprotection that is induced by glu-
cocorticoids plus LABAs in human airway smooth muscle and pro-
vide a rational explanation for the clinical efficacy of inhaled
corticosteroid (glucocorticoid)/LABA combinations in obstructive
airways diseases.
adrenoreceptor | beta-2-adrenergic receptor | protein kinase A |
glucocorticoid receptor | NR3C1
Asthma affects up to 300 million people globally, and chronicobstructive pulmonary disease (COPD), which is predomi-
nantly caused by cigarette smoking, is predicted to become the
third leading cause of death. Both diseases are characterized by
airflow limitation due, at least in part, to bronchoconstriction.
Therapeutically, long-acting β2-adrenoceptor agonists (LABAs),
short-acting β2-adrenoceptor agonists (SABAs), and inhaled glu-
cocorticoids, clinically known as inhaled corticosteroids (ICSs),
represent cornerstone treatments for both asthma and COPD (1,
2). Whereas SABAs provide short-term symptomatic relief of
bronchospasm, international practice guidelines recommend ICS/
LABA combination inhalers for asthma patients whose symptoms
are not adequately controlled on ICSmonotherapy (1). Moreover,
clinical guidelines recommend long-acting bronchodilators as a
first-line therapy for mild COPD and ICS/LABA combinations for
more severe disease (1, 2). In each case, large, multicenter ran-
domized controlled clinical trials convincingly show enhanced
clinical benefits to ICS/LABA combinations that are not achieved
by either component alone (2–4). However, despite the benefits
achieved by these combination therapies, there is a paucity of
mechanistic information accounting for these effects.
Several mediators, including acetylcholine, histamine, cysteinyl-
leukotrienes, and certain prostanoids, promote bronchocon-
striction, which is a defining characteristic of asthma and COPD (1,
2, 5). Such mediators contract airway smooth muscle (ASM) by
activating G-protein–coupled receptors (GPCRs) that typically
signal to phospholipase Cβ via the heterotrimeric G protein, Gq (6,
7). This leads to the formation of inositol(1,4,5)trisphosphate
(IP3), which stimulates the release of intracellular free Ca
2+
([Ca2+]i) from internal stores, and diacylglycerol, an activator of
protein kinase C, which, together with IP3, promotes ASM con-
traction (6, 7). Conversely, β2-adrenoceptor agonists are bron-
chodilators that functionally antagonize ASM contraction
irrespective of the constrictor (8). Current dogma holds that β2-
adrenoceptor agonism activates the cAMP/cAMP-dependent
protein kinase A (PKA) pathway to phosphorylate downstream
targets that oppose actin–myosin cross-bridge formation and re-
duce ASM force generation (8).
Signaling from GPCRs is terminated by GTPase-activating
proteins (GAPs) (9), which enhance the rate at which Gα subunits
hydrolyzeGTP.We show that the expression of the regulator of G-
protein signaling 2 (RGS2), a Gq selective GAP (10, 11), is tran-
scriptionally up-regulated by LABAs and that this is enhanced and
prolonged by glucocorticoids in human ASM. In vitro RGS2
down-regulates signaling from multiple Gq-coupled receptors and
in vivo imparts bronchoprotection against spasmogens. Increased
RGS2 gene expression therefore represents a genomic mechanism
of bronchoprotection, which may contribute to the therapeutic
activity of ICS/LABA combination therapies.
Results
RGS2 Expression Is Induced by LABAs and Enhanced by Glucocorticoids.
Primary human ASM cells were treated with maximally effective
concentrations of dexamethasone, the LABAs, salmeterol xina-
foate (salmeterol), formoterol fumarate (formoterol), and the
adenylyl cyclase activator, forskolin, before analysis for RGS2
mRNA (Fig. 1A and Fig. S1A) (12). Although RGS2 mRNA was
modestly induced by dexamethasone at all times, the LABAs
significantly induced RGS2 expression at 1 and 2 h, and forskolin
induced RGS2 mRNA at all times tested. In the presence of
LABAs or forskolin, dexamethasone significantly enhanced RGS2
expression at 1 and 2 h. This effect was more than the sum of the
components and is therefore described as synergy. At 6 h, neither
LABAs nor dexamethasone significantly increased RGS2 mRNA,
yet the combination significantly induced RGS2 mRNA.
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To explore the mechanistic basis for this effect, unspliced nu-
clear RNA (nRNA) corresponding to the exon 1–intron A and
exon 4–intron D splice junctions in RGS2 was examined as an
index of transcription rate (Fig S1B). Because splicing reactions
are not limiting and occur very rapidly (13), the transient accu-
mulation of unspliced nRNA is a surrogate of transcription rate
(14, 15). TaqMan PCR for the RGS2 exon 1–intron A slice junc-
tion revealed a very rapid increase induced by salmeterol that was
further enhanced by dexamethasone (Fig. 1A). This effect had
declined by 6 h, but in the presence of dexamethasone was still
significantly induced. An identical effect was observed for the
RGS2 exon 4–intron D junction (Fig. S1C).
To examine a role for mRNA stability, ASM cells were tested in
standard actinomycin D chase experiments. Following either no
treatment or stimulation with dexamethasone, salmeterol, or sal-
meterol plus dexamethasone for 2 h, actinomycin D was added,
and decay of RGS2 mRNA was monitored by real-time RT-PCR
(Fig. 1B). No significant changes in RSG2 mRNA stability were
detected between any treatment group. Taken with the nRNA
data, this clearly shows the increasedRGS2mRNAexpression due
to LABAs and that the enhancement and prolonged expression in
the presence of glucocorticoid are primarily due to themodulation
of gene transcription.
RGS2 protein expression revealed variable and barely detec-
tible increases by the glucocorticoids, fluticasone propionate (FP),
budesonide, and dexamethasone (Fig. 1C; Fig. S2 A and B; Fig.
S3A). Conversely, salmeterol and formoterol strongly induced
RGS2 expression, which peaked at 2 h (Fig. 1C; Figs. S2 and S3).
This was mimicked by forskolin, but the duration of RGS2 ex-
pression was prolonged. The presence of FP further elevated sal-
meterol- and forskolin-induced RGS2 expression at 1 and 2 h,
and, at times thereafter, RGS2 expression was dramatically pro-
longed (Fig. 1C). Indeed, salmeterol plus FP induced RGS2 pro-
tein from 45 min to 18 h posttreatment, with a plateau of near
maximal expression between 2 and 8 h (Fig. 1D and Fig. S2).
Similar data were described for salmeterol plus dexamethasone
and formoterol plus budesonide (Figs. S2 and S3). The up-regu-
lation of RGS2 expression by salmeterol or by salmeterol plus FP
was attenuated by the β2-adrenoceptor selective antagonist, ICI
118,551 (Fig. S3C). This confirms the selectivity for the β2 adre-
noceptors. Similarly, the ability of salmeterol or salmeterol plus
dexamethasone to induce RGS2 expression was totally prevented
by the RNA polymerase II inhibitor, actinomycin D, and is con-
sistent with transcriptional control (Fig. S3D).
To explore the role of PKA, cells were infected with adenovirus
overexpressing PKIα, a highly selective and potent inhibitor of
PKA (16). Using this method, virtually all ASM cells express PKIα,
and this inhibits cAMP response element (CRE) binding protein
(CREB) phosphorylation and CRE-dependent transcription (17,
18). Induction of RGS2 protein by salmeterol was blocked by Ad5-
PKIα, but not by the control Ad5-lacZ (Fig. 1E). In the presence of
salmeterol plus FP, RGS2 protein was strongly induced and was
also inhibited by Ad-PKIα, but not by Ad5-LacZ (P < 0.001 rel-
ative to either naive or Ad5-LacZ using ANOVA with a Bonfer-
roni post test). These data support a PKA-dependent mechanism
for the induction of RGS2 by LABAs.
Repression of [Ca2+]i Flux by LABAs Is Prolonged by Glucocorticoid. In
human ASM, histamine increased [Ca2+]i with near maximal
responses at 10 μM (Fig. 2A). This was blocked by mepyramine, a
histamine H1 receptor antagonist (19), and 2-aminoethyldiphenyl
borate (2-APB), an IP3R antagonist (20) (Fig. 2B). Because the H1
receptor couples to Gq (19), this confirms a Gq/IP3/IP3R pathway
linked to [Ca2+]i flux. Similarly, the acetylcholine analog, meth-
acholine, contracts ASM via the Gq-linked muscarinic M3 re-
ceptor (6, 19). In the current study, methacholine-induced [Ca2+]i
was maximal at 30 μM and was blocked by 2-APB (Fig. S4 A and
B). Likewise, the thromboxane analog, U46619, which is selective
for the Gq-linked thromboxane receptor (TP) (19), maximally in-
creased [Ca2+]i at 1 μM and this was blocked by 2-APB, again
supporting a conventional Gq-linked pathway leading to elevated
[Ca2+]i (Fig. S4 C and D).
Because RGS2 expression was maximal 2 h after LABA addi-
tion and because this was prolonged to at least 6 h by glucocorti-
coid, the protective role of these treatments was tested on
spasmogen-increased [Ca2+]i. Following a 2-h pretreatment, sal-
meterol and salmeterol plus dexamethasone, but not dexametha-
sone alone, significantly attenuated histamine-, methacholine-, or
U46619-induced [Ca2+]i (Fig. 2C). However, after a 6-h pre-
treatment, only salmeterol plus dexamethasone significantly attenu-
ated histamine-, methacholine-, and U46619-induced increases in
[Ca2+]i relative to control, salmeterol, or dexamethasone alone
(Fig. 2C). To explore this effect, ASM cells were pretreated with
dexamethasone, salmeterol, or salmeterol plus dexamethasone
for various times before stimulation with histamine (Fig. 2D).
Whereas dexamethasone failed to alter histamine-induced [Ca2+]i,
salmeterol significantly repressed [Ca2+]i following 1-, 2-, and 4-h
pretreatments, and salmeterol plus dexamethasone provided sig-




Fig. 1. Expression of RGS2 in human ASM cells. (A) Primary human ASM
cells were treated with combinations of 1 μM dexamethasone (Dex) or 100
nM salmeterol (Salm). Cells were harvested for real-time PCR analysis of
RGS2 and GAPDH mRNAs (Upper) or unspliced RGS2 nuclear RNA (nRGS2)
and U6 RNA (Lower). (Upper) Data (n = 9), expressed as RGS2/GAPDH, are
plotted as fold relative to untreated (at t = 1 h) as means ± SE. (Lower) Data
(n = 10) are plotted as nRGS2/U6 as means ± SE. Multiple comparisons at
each time were made using ANOVA with a Bonferroni post test. Significance
data relative to untreated samples are *P < 0.05, **P < 0.01, and ***P <
0.001. Significance data relative to Dex-treated samples are aP < 0.05, bP <
0.01, and cP < 0.001. Significance data relative to Salm-treated samples are
dP < 0.05, and eP < 0.01. (B) Primary human ASM cells were not stimulated
(NS) or treated with Dex (1 μM), Salm (100 nM), or Dex (1 μM) + Salm (100
nM). After 2 h, actinomycin D (10 μg/mL) was added and RNA was harvested
at 15, 30, 60, 120, and 240 min for RT-PCR analysis of RGS2 and GAPDH. Data
(n = 7 for 15, 30, and 60 min; n = 3 for 120 and 240 min) expressed as RGS2/
GAPDH are plotted as a percentage of their respective treatment at t = 0
(i.e., when actinomycin D was added) as means ± SE. (C) Cells as in A were
treated with 300 nM fluticasone propionate (FP), 100 nM salmeterol (Salm),
and 10 μM forskolin (Forsk) before Western blot analysis of RGS2 and
GAPDH. Blots representative of four such experiments are shown. (D) Pri-
mary human ASM cells were treated with 100 nM salmeterol plus 300 nM
fluticasone propionate (Salm + FP) before Western blotting for RGS2 and
GAPDH. Blots representative of four experiments are shown. (E) Primary
human ASM cells were left naive or infected with Ad5-PKI or Ad5-LacZ. After
24 h, cells were treated with 300 nM fluticasone propionate (FP) and/or 100
nM salmeterol (Salm) for 6 h before Western blot analysis for RGS2 and
GAPDH. Blots representative of three such experiments are shown. Densi-
tometric data for C and D are provided in Fig. S2.
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illustrates the enhanced protective effect afforded by the LABA/
glucocorticoid combination.
RGS2 Attenuates Agonist-Induced Increases in [Ca2+]i. Following in-
fection of primary human ASM cells with RGS2-expressing ade-
novirus, RGS2 expression correlated with multiplicity of infection
(MOI) and reduced [Ca2+]i flux elicited by histamine (Fig. 3 A and
B). At all MOIs, repression was significant relative to Ad5-LacZ
and was reproduced for methacholine and U46619 (Fig. 3B and
Fig. S4E). Similarly, bradykinin, LTB4, LTD4, and misoprostol,
which act on the Gq-linked B1 and B2, BLT1 and BLT2, CysLT1
and CysLT2, and EP3 receptors, respectively (19), all elicited in-
creased [Ca2+]i that was significantly repressed by Ad5-RGS2, but
not by LacZ-expressing virus (Fig. S4F). Importantly, KCl-induced
[Ca2+]i, a receptor-independent stimulus, was unaffected by
Ad5-RGS2 (Fig. 3C). Thus, RGS2 attenuates procontractile
responses produced by Gq-linked GPCR agonists in primary hu-
man ASM cells.
Gene silencing by two targeting, but not control, siRNAs ro-
bustly reduced salmeterol plus dexamethasone-induced RGS2
expression (Fig. 3D). Following a 6-h incubation with salmeterol
plus dexamethasone, repression of histamine-increased [Ca2+]i
was evident in naive and control siRNA-treated cells (Fig. 3E and
Fig. S4G). However, the two RGS2-targeting siRNAs prevented
this, and equivalent effects were shown for methacholine and
U46619 (Fig. 3E and Fig. S4G). Conversely, 2 h of salmeterol plus
dexamethasone repressed agonist-increased [Ca2+]i, but this was
unaffected by RGS2-targeting siRNAs (Fig. S4G). Because
RGS2 is strongly expressed at both times (Fig. 1 and Fig. S3), we
propose that RGS2 is an essential and primary effector of re-
pression at 6 h, but that non-RGS2 repressive mechanisms exist
with shorter treatments.
RGS2 Is Bronchoprotective. Given a causal relationship between
elevated [Ca2+]i and ASM contraction (6, 7), the above data
imply that RGS2 prevents ASM contraction. This was tested in
an experimental model using Rgs2-deficient (Rgs2−/−) C57/Bl6
mice (Fig. S5A) (21). Following PCR genotyping (Fig. S5 A and
B), tracheas were removed for analysis of isometric force gen-
erated by the trachealis muscle (Fig. 4A). Methacholine con-
centration dependently increased tension in wild-type animals
with a peak of 294 ± 22% compared with the effect of 100 mM
KCl. With trachealis from Rgs2−/− littermates, methacholine
achieved greater peak tensions (523 ± 104%) (Fig. 4A). Rgs2
protein was expressed in wild type, but not in Rgs2−/− tracheas
(Fig. 4A, Lower).
Lung function of wild-type, Rgs2+/−, and Rgs2−/− animals was
compared using the SciReq Flexivent system (22). Lung re-
sistance and compliance were measured at baseline, following
inhalation of nebulized PBS, methacholine, or 5-hydroxytrypta-
mine (5-HT) (Fig. 4B). No differences in baseline resistance, or
following PBS inhalation, were detected between wild-type, het-
erozygote, or knockout animals. Increasing methacholine doses
modestly increased resistance in wild-type animals, and this was
significantly enhanced in Rgs2−/− animals (Fig. 4B). Hetero-
zygotes revealed an intermediate phenotype. Similar data were
obtained for 5-HT except that knockout animals showed elevated
resistance at all 5-HT doses (Fig. 4B). Lung compliance (inverse
of stiffness) was significantly lower in knockout and heterozygote
animals compared with wild-type counterparts (Fig. 4B). In re-
sponse to inhaled methacholine or 5-HT, all animals showed re-
duced compliance. Knockout animals exhibited the lowest
compliance, and heterozygotes were an intermediate phenotype.
Graded expression of Rgs2 was confirmed (Fig. S5C). Because
pathology may affect lung function, lungs were removed for his-
tological examination by hematoxylin and eosin staining (for
inflammation), periodic acid Schiff staining (for mucus), and dif-
ferential cell counting in bronchoalveolar lavage fluid. No dif-
ferences were detected between wild-type, Rgs2+/−, and Rgs2−/−
mice (Fig. S6).
In cultured mouse tracheal cells (MTCs) expressing the smooth
muscle markers α-smooth muscle actin and calponin (Fig. S7A),
salmeterol plus dexamethasone induced Rgs2 expression and re-
duced methacholine-, U46619-, and 5-HT–induced increases in
[Ca2+]i (Fig. S7 B and C). Conversely, in Rgs2
−/− MTCs, there was
no Rgs2 and no protection by salmeterol plus dexamethasone
against agonist-increased [Ca2+]i (Fig. S7 B and C). Although this
establishes a functional role for Rgs2 in MTCs, regulation of
mouse Rgs2 differed from human ASM cells. Whereas salmeterol
induced Rgs2 protein with similar kinetics to human ASM and via
the β2-adrenoceptor (Fig. S7 D and E), there was no dexametha-
sone enhancement in MTCs. Therefore, LABA alone was used
in vivo to induce Rgs2 expression.
Two hours following intratracheal (i.t.) administration of aero-
solized formoterol, there was a dose-dependent protection against




Fig. 2. Effect of dexamethasone and salmeterol on agonist-enhanced [Ca2+]i
in human ASM cells. (A) Primary ASM cells loaded with Fluo4 were stimu-
lated with various concentrations of histamine. Representative traces
showing fluorescence/fluorescence at time 0 (F/F0) are plotted. Peak F/F0
from four such experiments are plotted as means ± SE. (B) Cells were treated
as in A except that 50 nM mepyramine (mep) or 10 μM 2-APB were added 30
min before a 10-μM histamine challenge. Data (mep, n = 6; 2-APB, n = 8) are
plotted as means of F/F0 ± SE. Significance was tested using a Student’s t test
where *P < 0.05 and ***P < 0.001. (C) Cells were treated as in A, except that
100 nM salmeterol (Salm) and/or 1 μM dexamethasone (Dex) were added 2
or 6 h before 10 μM histamine, 30 μM methacholine (MCh), or a 1-μM
U46619 challenge. Data (2 h pretreatment, n = 4; 6 h pretreatment, n = 8–10)
expressed as peak F/F0 are plotted as means ± SE. Multiple comparisons were
made using ANOVA with a Bonferroni post test. Significance data relative to
untreated samples are aP < 0.05, bP < 0.01, and cP < 0.001. Significance data
relative to Dex-treated samples are dP < 0.05, eP < 0.01, and fP < 0.001.
Significance between other groups is indicated where ***P < 0.001. (D) Cells
were pretreated with Dex (1 μM), Salm (100 nM), or Dex (1 μM) + Salm (100
nM) for the indicated times before challenge with histamine (10 μM) and
measurement of fluorescence. Peak F/Fo is plotted as means ± SE. Signifi-
cance relative to F/Fo induced by histamine was tested by ANOVA with
a Dunnett’s post test. **P < 0.01; ***P < 0.001.











correlated with Rgs2 expression (Fig. S8). Wild-type and Rgs2−/−
animals were therefore treated with i.t. formoterol for 2 h before
lung function analysis. Methacholine increased lung resistance and
reduced compliance in wild-type animals, and formoterol sig-
nificantly protected against these effects (Fig. 4C). In Rgs2−/−
animals, the changes in lung function induced by methacholine
were unaffected by formoterol. Basal and formoterol-induced
Rgs2 expression was confirmed in the lungs of wild-type, but not
of Rgs2−/−, animals (Fig. 4C). Thus, elevated RGS2 protects
against methacholine-induced increases in lung resistance and
loss of compliance.
Discussion
We describe the induction of RGS2 expression as a previously
unrecognized genomic mechanism of bronchoprotection that is
induced by LABAs and that is synergistically enhanced by gluco-
corticoids in human ASM cells. We propose that this represents an
important means by which ICS/LABA therapies effect superior
A B C
D E
Fig. 3. RGS2 attenuates agonist-induced [Ca2+]i primary human ASM cells. Primary human ASM cells were infected with the indicated MOIs of Ad5-RGS2.HA or
Ad5-LacZ. (A) After 24 h, cells were harvested for Western blot analysis of HA-tagged RGS2. Blots are representative of four such experiments. (B) Following
overnight incubation in serum-free media, cells were loaded with Fluo4 before stimulation with 10 μM histamine. Representative traces of F/Fo are shown and
peak F/Fo data from four experiments are plotted as means ± SE. (C) ASM cells were infected with 100 MOI of Ad5-RGS2.HA or Ad5-LacZ or left naive. As in B,
cells were challenged with 60 mM potassium chloride (KCl). Peak F/Fo (n = 4) is plotted as means ± SE. Comparisons relative to control (Ad5-LacZ) were made by
Student’s t test. (D) Primary human ASM cells were transfected with the indicated siRNAs before treatment with 100 nM salmeterol plus 1 μM dexamethasone
(Salm + Dex) for 6 h. Western blotting for RSG2 and GAPDH was performed. Blots representative of five experiments are shown. (E) Alternatively, cells were
loaded with Fluo4 before a 10-μM histamine challenge. Representative traces of F/Fo from nine such experiments are shown (Fig. S4G).
A B
C
Fig. 4. Rgs2 is bronchoprotective. (A) Equilibrated strips of
mouse trachealis smooth muscle from wild type (WT) or Rgs2−/−
knockout (KO) animals were challenged with KCl (100 mM). At
peak contraction, muscle strips were washed free of KCl and re-
equilibrated. Cumulative concentration-response curves (n =
11–15) were constructed to methacholine (MCh) and plotted as
a percentage of the KCl-induced response as means ± SE.
Trachealis muscles were subsequently Western blotted for Rgs2
and Gapdh. Data from three animal pairings are shown.
Comparisons were made using a Mann–Whitney U test. Sig-
nificance relative to the relevant wild-type control sample is
*P < 0.05. (B) Wild type (WT), Rgs2−/+ heterozygous (Het), and
Rgs2−/− knockout (KO) mice were subjected to lung function
analysis. Total lung resistance (Upper panels) and compliance
(Lower panels) was measured at baseline (Left panels), fol-
lowing inhalation of nebulized PBS and PBS containing in-
creasing concentrations of methacholine (Center panels) or
5-HT (Right panels). Data (n = 6–16) are plotted as cm H2O/s/mL
(resistance) or ml/cm H2O (compliance) as means ± SE. (C) Wild
type (WT) (Left panels) and Rgs2 knockout (KO) (Right panels)
animals were treated by i.t. instillation with 50 μL of 0.9% sa-
line or 0.5 mg/kg formoterol (Form). After 2 h, mice were
anesthetized before lung function analysis. Total lung re-
sistance (Upper panels) and compliance (Lower panels) were
measured in response to increasing concentrations of nebu-
lized methacholine. Data (n = 4–6) are plotted as cm H2O/s/mL
or ml/cm H2O as means ± SE. Lungs (n = 4) were subsequently
Western blotted for Rgs2 and Gapdh.
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control of symptoms in diseases such as asthma or COPD. Thus,
international guidelines for the management of asthma and COPD
indicate stepwise increases in the intensity of pharmacotherapy
moving from inhaled monotherapies to inhaled ICS/LABA com-
binations (1, 2). For example, mild-to-moderate asthmatics are
generally prescribed regular ICS whereas more severe disease
requires ICS/LABA combinations, which enhance the therapeutic
effectiveness of the ICS to a level that cannot be achieved by ICS
alone (23). Conversely, in COPD, LABAs represent an initial
maintenance medication, which, in more advanced disease, is in-
creased to ICS/LABA combinations. Equally, bronchiolitis is a
major cause of hospitalization in infants of less than 1 y and is poorly
controlled by conventional monotherapies (24). However, inhaled
epinephrine, which will activate β2-adrenoceptors on ASM, com-
bined with dexamethasone (epinephrine and dexamethasone were
ineffective alone), significantly reduced hospitalization rates in
these infants (25). Thus, multiple strands of clinical evidence sup-
port a positive, synergistic interaction between the agonist of the β2-
adrenoceptor and the glucocorticoid receptor (GR). Our current
study offers some explanation for this effect (23).
Mechanistically, β2-adrenoceptor agonists can synergistically
enhance glucocorticoid actions, and this may contribute to the
enhanced efficacy of ICS/LABA combinations (12, 23). However,
we show RGS2 to be a PKA-dependent effector gene, whose ex-
pression in human ASM promotes bronchoprotection and is syn-
ergistically enhanced by glucocorticoids. Functionally, RGS2 is a
GAP that switches off signaling fromGq-coupled GPCRs (10, 26),
including muscarinic M1 and M3 receptors (27, 28), and we con-
firm this for multiple other receptors that are relevant to lung
disease. Importantly, combinations of LABA plus glucocorticoid
enhance and extend RGS2 expression in human ASM, and loss of
RGS2 expression prevents the prolonged protective effect of the
combination against agonist-enhanced [Ca2+]i. In vivo, loss of
RGS2 produces a hyperactive phenotype with increased lung re-
sistance and reduced compliance. This is consistent with the hy-
pertensive effect of RGS2 loss in the vasculature and confirms
a bronchoprotective role in the lung (29, 30). Furthermore, the
ability to induce RGS2 expression in vivo further protects against
spasmogen-increased lung resistance and reductions in compli-
ance. Thus, the extended induction of RSG2 in ASM by ICS/
LABA combination therapies should provide superior protection
from multiple spasmogens that act on Gq-coupled GPCRs in
asthma, COPD, or bronchiolitis and other diseases.
Induction of RGS2 expression by β2-adrenoceptor agonists and
forskolin implies a classical cAMP pathway leading rapidly to
RGS2 gene expression and is consistent with isoproterenol in-
ducing RGS2mRNA in rat astrocytoma cells (31). Roles for the β2-
adrenoceptor and PKA were confirmed by preventing RGS2 ex-
pression in the presence of ICI 118,551 or PKIα and is supported
for forskolin, which induces CREB binding to CRE sites in the
proximal RGS2 promoter (32). Likewise, the ability of gluco-
corticoids to synergistically enhance RGS2 expression could sim-
plistically involve enhanced β2-adrenoceptor expression, coupling,
or reduced receptor desensitization (see ref. 8 and references
therein). However, these effects are not likely to occur acutely
and in any event may not be important in ASMdue to the large β2-
adrenoceptor reserve (33). More likely, as RGS2 is a glucocorti-
coid-responsive gene (15, 34) with an established GR-binding
region (35), there is a direct interaction of the cAMP and glu-
cocorticoid pathways at the level of promoter activation. Cer-
tainly, our data support a mechanism that involves transcriptional
induction of RGS2 because the level of unspliced nuclear RGS2
RNAwas both enhanced and prolonged in the presence of LABA
plus glucocorticoid. Because there was no obvious effect on
RGS2 mRNA stability, and because protein expression correlates
well with mRNA expression, these data support transcriptional
control as the major effector mechanism governing RGS2 ex-
pression in human ASM cells. Furthermore, the use of three
structurally distinct GR ligands with differing selectivities for
other nuclear hormone receptors, including the progesterone,
mineralocorticoid, androgen, and estrogen receptors (4),
excludes their involvement and supports a role for GR. This
interaction between the glucocorticoid and cAMP pathways
requires formal investigation and should be tested alongside
other physiological agents, such as parathyroid hormone or
angiotensin II, which also induce RSG2 expression (36, 37).
Importantly, knockdown of RGS2 expression in human ASM
cells did not prevent attenuation of spasmogen-enhanced [Ca2+]i
following 2 h of salmeterol plus dexamethasone. Given the pres-
ence of RGS2 protein, classical mechanisms of bronchoprotection
must operate to create functional redundancy. However, the
protective effect of 6 h of salmeterol plus dexamethasone on hu-
man ASM was totally prevented by RGS2 knockdown. This indi-
cates that elevated RGS2 gene expression is the dominant
protective mechanism and clearly illustrates how ICS/LABA
combinations may confer enhanced therapeutic benefit. Indeed,
the 12-h protection from spasmogen-induced [Ca2+]i afforded by
salmeterol plus dexamethasone, compared with just 4 h for sal-
meterol alone, further demonstrates the potential advantage due
to RGS2. In this context, it is salient to note that the effects due to
RGS2 occur on a background of other RGS proteins, including
RGS3, -4, and -5, which are all relatively highly expressed in hu-
man ASM cells (38). Indeed, somewhat paradoxically, β-agonists
reduce RGS5 expression, and this may be expected to reduce some
of the benefit conferred by elevation of RGS2 (38).
These data also highlight important differences between mice
and humans. First, human RSG2 is synergistically induced by
LABAs and glucocorticoids, whereas mouse Rgs2 is induced only
by LABAs. Thus, the mouse models Rgs2 function, but not gene
regulation. Second, mouse Rgs2 function is nonredundant when
induced by LABA alone. In this regard, there is persuasive evi-
dence suggesting that the classical bronchodilatory effects of
β-adrenoceptor agonists are mediated via the β1, rather than the
β2, subtype in the mouse (39). Thus, β2-adrenoceptor agonists are
poor bronchodilators in the mouse, and this explains why non-
selective agonists are more effective and potent bronchodilators
than β2-selective agonists (40). Nevertheless, our data clearly show
that β2-adrenoceptor agonists induce the expression of Rgs2 and
that this leads to a significant nonredundant bronchoprotective
effect that is absent in Rgs2−/− animals.
In summary, the induction of RGS2 gene expression provides
bronchoprotection, which, in the context of β2-adrenoceptor
monotherapy, is likely to be largely redundant because of acute,
nongenomic mechanisms of relaxation/bronchoprotection. How-
ever, in the clinical context of ICS/LABA combination therapies,
RGS2 expression may be enhanced and prolonged. Under this
condition, the genomic induction of RGS2 becomes the pre-
dominant effector for protecting against bronchoconstrictor medi-
ators. This represents a fundamental shift in our understanding of
how sympathomimetic bronchodilators improve symptom control
in diseases such as asthma, COPD, or acute bronchiolitis. In terms
of drug discovery, drugs, or drug combinations, that enhance and/or
prolong RGS2 expression are, like ICS/LABA combinations, pre-




wild-type, Rgs2 heterozygous (Rgs2+/−), and knockout (Rgs2−/−) mice were bred
in-house through Rgs2+/− × Rgs2+/− crosses (21, 30). Protocols were approved by
the University of Calgary Animal Care Committee, according to the Canadian
Council for Animal Care guidelines. Mice were age and sex matched between
different genotype groups. Where appropriate, mice were anesthetized with
isofluorane before i.t administration of aerosolized 0.9% NaCl or formoterol
using a MicroSprayer aerosolizer (Penn-Century) (41). Isolated ASM cells from
normal human lungs were grown in Dulbecco’s Modified Eagle Medium (Invi-
trogen) and incubated in serum-free medium before experiments (12).











RNA Isolation and Real-Time PCR. RNA extractions and real-time PCR (SYBR
GreenER chemistry) for GAPDH was as described (15). Amplification primers
were RGS2 forward (5′-CCT CAA AAG CAA GGA AAA TAT ATA CTG A-3′) and
reverse (5′-AGT TGT AAA GCA GCC ACT TGT AGC T-3′). TaqMan analysis of
unspliced nuclear RGS2 is described in SI Materials and Methods.
Western Blotting, siRNA Knockdown, and Adenoviral Infections. Western
blotting, siRNA transfections, and adenoviral infections were as described
(42). siRNA-targeted sequences were RGS2 siRNA 2 (SI00045773; 5′-AAC GTG
GTG TCT CAC TCT GAA-3′); RGS2 siRNA 6 (SI03036082; 5′-AAG GGT ATA CAG
CTT GAT GGA-3′) (Qiagen); and green fluorescent protein siRNA (control
siRNA) (P-002048–03-20; 5′-GGC AAG CTG ACC CTG AAG TTC-3′) (Dharma-
con). Cells were infected with 300 MOI of Ad5-RGS2.HA (43) or Ad5-LacZ for
24 h before experiments.
Calcium Assay. [Ca2+]i release was measured using Fluo4 NW according to the
manufacturer’s instructions (Invitrogen). Confluent cells were loaded for 30
min at room temperature with Fluo-4. Using 494 nm excitation, basal fluo-
rescence (F0) was measured at 516 nm for 1.6 s (FLUOstar OPTIMA plate
reader, BMG Labtech). Agonists were injected and fluorescence (F) was
measured. Values expressed as F/F0 are a proxy for [Ca
2+]i.
Lung Function.Mice were anesthetized by intraperitoneal injection of sodium
pentobarbital (50 mg/kg) (CEVA Santé Animale) and intramuscular injection
of ketamine hydrochloride (90 mg/kg) (Wyeth). Tracheostomized mice were
connected to a flexivent small animal ventilator (SciReq) before challenge
with increasing concentrations of aerosolized drugs administered via an in-
line nebulizer. Resistance and compliance were measured using a snapshot
150 perturbation (22).
Isometric Force Measurement. Mice were euthanized with 200 mg/kg pen-
tobarbital and exsanguination. Excised tracheas were divided into four equal
pieces before placing in oxygenated Krebs–Henseleit solution (KHS) (33).
Strips were mounted vertically under a tension of 6 mN in oxygenated KHS
at 37 °C. After equilibration with frequent washing for at least 120 min
before experiments, changes in tension were measured isometrically (33).
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